Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. (Q50850848)

24 March 2018

title

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. (English)

1 reference

24 March 2018

4

Cigdem Erten

1 reference

24 March 2018

Yuksel Kucukzeybek

6

object named as

Yuksel Kucukzeybek

1 reference

24 March 2018

Mustafa Oktay Tarhan

14

object named as

Mustafa Oktay Tarhan

1 reference

24 March 2018

Lutfiye Demir

1

object named as

Lutfiye Demir

1 reference

24 March 2018

author name string

Seyran Yigit

2

1 reference

24 March 2018

Hulya Ellidokuz

3

1 reference

24 March 2018

Isil Somali

5

1 reference

24 March 2018

Ahmet Alacacioglu

7

1 reference

24 March 2018

Suna Cokmert

8

1 reference

24 March 2018

Alper Can

9

1 reference

24 March 2018

Murat Akyol

10

1 reference

24 March 2018

Ahmet Dirican

11

1 reference

24 March 2018

Vedat Bayoglu

12

1 reference

24 March 2018

Aysegul Akder Sari

13

1 reference

24 March 2018

publication date

9 July 2013

1 reference

24 March 2018

Clinical & Experimental Metastasis

published in

1 reference

24 March 2018

volume

30

1 reference

24 March 2018

issue

8

1 reference

24 March 2018

page(s)

1047-1062

1 reference

24 March 2018

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Towards a novel classification of human malignancies based on gene expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Prognostic impact of FOXP3 expression in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-013-9602-9

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma

21 January 2018

1 reference

12 December 2020

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

1 reference

12 December 2020

The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer

1 reference

12 December 2020

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

12 December 2020

Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2

1 reference

12 December 2020

A single-center experience with inflammatory breast cancer, 1985-2003

1 reference

12 December 2020

Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival

1 reference

12 December 2020

CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes

1 reference

12 December 2020

Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast

1 reference

12 December 2020

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

1 reference

12 December 2020

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer

1 reference

12 December 2020

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

1 reference

12 December 2020

Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

1 reference

12 December 2020

Prognostic value of initial clinical disease stage after achieving pathological complete response

1 reference

12 December 2020

Annual hazard rates of recurrence for breast cancer after primary therapy.

1 reference

12 December 2020

Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients

1 reference

12 December 2020

10.1007/S10585-013-9602-9

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018